ELSEVIER

International Journal of Antimicrobial Agents 4 (1994) 337–339

INTERNATIONAL JOURNAL OF
Antimicrobial
Agents

Author Index

Akamatsu, H. see S. Nishijima (4) 147
Alpert, N.M. see R.H. Rubin (4) S15
Andrei, G. see R. Snoeck (4) 211
Andrews, J.M. see D. Honeybourne (4) 151
Andriole, V.T., Fleroxacin: the newly introduced once-daily quinolone (4) S1
Andriole, V.T. and D. Lew, Conclusion (4) S59
Aneja, N. see J. Dogra (4) 309
Asada, Y. see S. Nishijima (4) 147

Babich, J. see R.H. Rubin (4) S15
Bailey, R.R., Management of uncomplicated urinary tract infections (4) 95
Baldwin, D.R. see D. Honeybourne (4) 151
Baurecht, W. see K.G. Naber (4) 197
Borner, K. see H. Lode (4) S47
Bouter, A.S., K.P.M. van Kessel, J.J. Cornelissen, J.F.P. Schellekens, Y.Y. van der Hoek, H. Snippe and J. Verhoef, Antibiotics enhance binding of lipid A-specific murine monoclonal antibody E5 to Gram-negative bacteria (4) 191
Bryant, A.E. see D.L. Stevens (4) 297
Bujdáková, H. and M. Múčková, Antifungal activity of a new benzothiazole derivative against *Candida* in vitro and in vivo (4) 303

Capobianco, J.O. and R.C. Goldman, Macrolide transport in *Escherichia coli* strains having normal and altered OmpC and/or OmpF porins (4) 183
Chang, S.-C., W.-C. Hsieh and K.-T. Luh, Resistance to antimicrobial agents of common bacteria isolated from Taiwan (4) 143
Chibante, A., E. Peixoto, R. Lejeune, K. Winter and M. Kissling, Clinical efficacy and safety of cefetamet pivoxil in toddlers (4) 203
Cleeland, R. see R.H. Rubin (4) S15
Cleeland, R. see D.W. Morck (4) S21
Cornelissen, J.J. see A.S. Bouter (4) 191
Costerton, J.W. see D.W. Morck (4) S21

De Clercq, E. see R. Snoeck (4) 211
Degreef, H. and Famciclovir Herpes Zoster Clinical Study Group, Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients (4) 241
Dekio, S. see H. Saito (4) 175
Dellamonica, P., Cefuroxime axetil (4) 23
Dogra, J. and N. Aneja, Leishmaniasis and itraconazole: a controlled clinical trial on cutaneous subtypes (4) 309

Ellis, B.D. see D.W. Morck (4) S21

Famciclovir Herpes Zoster Clinical Study Group see H. Degreef (4) 241
Fischer, M. see K.G. Naber (4) 197
Fischman, A.J. see R.H. Rubin (4) S15
Freeman, C.D., C.H. Nightingale and R. Quintiliani, Minocycline: old and new therapeutic uses (4) 325
Fujita, M. see S. Nishijima (4) 147

Geerts, S., The efficacy of praziquantel for the treatment of cestode and metacestode infections (4) 321
Georgiev, V.S., Treatment and developmental therapeutics of *Mycobacterium avium* complex (MAC) infections (4) 247
Georgiev, V.S., Treatment and developmental therapeutics of *Mycobacterium tuberculosis* infections (4) 157
Gleckman, R., Complicated urinary tract infections (4) 125
Goldman, R.C. see J.O. Capobianco (4) 183
Graninger, W., C. Wenisch and E. Presterl, Quinolones in the treatment of complicated urinary tract infection (4) S29
Greaves, I. see D. Honeybourne (4) 151
Grüneberg, R.N. see A.P.R. Wilson (4) S1
Gryseels, B. see V. Kumar (4) 313
Guglielmo, B.J., M.L. Stoller and R.A. Jacobs, Management of candiduria (4) 135

0924-8579/94/$26.00 © 1994 Elsevier Science B.V. All rights reserved

Harding, G.K.M. and A.R. Ronald, The management of urinary infections: what have we learned in the past decade? (4) 83
Harris, M. see D. Honeybourne (4) 151
Hedges, S. and C. Svanborg, The mucosal cytokine response to urinary tract infections (4) 89
Hoepelman, I.M., Urinary tract infection in patients with diabetes mellitus (4) 113
Höffken, G. see H. Lode (4) S47
Honeybourne, D., I. Greaves, D.R. Baldwin, J.M. Andrews, M. Harris and R. Wise, The concentration of sparfloxacin in lung tissues after single and multiple oral doses (4) 151
Hsieh, W.-C. see S.-C. Chang (4) 143
Hustinx, W.N.M. and H.A. Verbrugh, Catheter-associated urinary tract infections: epidemiological, preventive and therapeutic considerations (4) 117

Jacobs, R.A. see B.J. Guglielmo (4) 135

Kallová, J. see P. Milošovič (4) 69
Kawabata, S. see S. Nishijima (4) 147
Kettner, M. see P. Milošovič (4) 69
Kissling, M. see A. Chibante (4) 203
Klugman, K.P., Pneumococcal resistance to the third-generation cephalosporins: clinical, laboratory and molecular aspects (4) 63
Korzeniowski, O.M., Host defense mechanism in the pathogenesis of UTI and UTI in immunocompromised patients (4) 101
Kresken, M. see K.G. Naber (4) 197
Kumar, V. and B. Gryseels, Use of praziquantel against schistosomiasis: a review of current status (4) 313

Lam, K. see D.W. Morck (4) S21
Lejeune, R. see A. Chibante (4) 203
Lew, D., Opportunities for i.v. to oral switch in the management of infections: the role of quinolones (4) S53
Lew, D. see V.T. Andriole (4) S59
Lindner, B. see M. Wiese (4) 271
Liu, Y.-Y. see R.H. Rubin (4) S15
Livni, E. see R.H. Rubin (4) S15
Lode, H., T. Schaberg, G. Höffken and K. Borner, Use of fluoroquinolones in lower respiratory tract infections (LRTI) (4) S47
Luh, K.-T. see S.-C. Chang (4) 143

Mačičková, T. see P. Milošovič (4) 69
McKay, S.G. see D.W. Morck (4) S21
Meunier, F., Current issues on the prophylaxis and the management of fungal infections in leukemic patients (4) 73
Milošovič, P., T. Mačičková, M. Kettner and J. Kallová, Development of amikacin resistance in bacterial isolates in Slovakia (1990–1992) (4) 69
Morck, D.W., K. Lam, S.G. McKay, M.E. Olson, B. Prosser, B.D. Ellis, R. Cleeland and J.W. Costerton, Comparative evaluation of fleroxacin, ampicillin, trimethoprim-sulfamethoxazole, and gentamicin as treatments of catheter-associated urinary tract infection in a rabbit model (4) S21
Múčková, M. see H. Bujdáková (4) 303

Naber, K.G., W. Baurecht, M. Fischer and M. Kresken, Pefloxacin single-dose in the treatment of acute uncomplicated lower urinary tract infections in women: a meta-analysis of seven clinical trials (4) 197
Naber, K.G., Uncomplicated urinary tract infections — is single-dose therapy effective? (4) S39
Namura, S. see S. Nishijima (4) 147
Neu, H. see A.P.R. Wilson (4) S1
Nicolau, D.P. see C.O. Onyeji (4) 281
Nicolle, L.E., Consequences of asymptomatic bacteriuria in the elderly (4) 107
Nightingale, C.H. see C.O. Onyeji (4) 281
Nightingale, C.H., Implications of fleroxacin's pharmacokinetic profile (4) S7
Nightingale, C.H. see C.D. Freeman (4) 325
Nishijima, S., S. Namura, H. Akamatsu, Y. Asada, S. Kawabata and M. Fujita, Activity of eight fluoroquinolones against methicillin-resistant *Staphylococcus aureus* isolated from cutaneous infections (4) 147
Norrby, S.R., Useful agents in the management of urinary tract infections (4) 129

Olson, M.E. see D.W. Morck (4) S21
Onyeji, C.O., C.H. Nightingale, D.P. Nicolau and R. Quintiliani, Activities of liposome-encapsulated azithromycin and rifabutin compared with that of clarithromycin against *Mycobacterium avium–intracellulare* complex in human macrophages (4) 281

Peixoto, E. see A. Chibante (4) 203
Presterl, E. see W. Graninger (4) S29
Prosser, B. see D.W. Morck (4) S21
Prosser, B.L.T. see R.H. Rubin (4) S15

Quintiliani, R. see C.O. Onyeji (4) 281

Quintiliani, R. see C.D. Freeman (4) 325

Ronald, A.R. see G.K.M. Harding (4) 83
Rubin, R.H., E. Livni, J. Babich, N.M. Alpert, Y.-Y. Liu, R. Cleeland, B.L.T. Prosser, E. Thom and A.J. Fischman, Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography (4) S15

Saito, H., H. Tomioka, K. Sato and S. Dekio, In vitro and in vivo activities of clarithromycin against the *Mycobacterium avium* complex (4) 175
Sato, K. see H. Saito (4) 175
Schaberg, T. see H. Lode (4) S47
Schellekens, J.F.P. see A.S. Bouter (4) 191
Seydel, U. see M. Wiese (4) 271
Snippe, H. see A.S. Bouter (4) 191
Snoeck, R., G. Andrei and E. De Clercq, Chemotherapy of varicella zoster virus infections (4) 211
Stevens, D.L., A.E. Bryant and S. Yan, Invasive group A streptococcal infection: new concepts in antibiotic treatment (4) 297
Stoller, M.L. see B.J. Guglielmo (4) 135
Svanborg, C. see S. Hedges (4) 89

Thom, E. see R.H. Rubin (4) S15
Todd, W.M., Cefpodoxime proxetil: a comprehensive review (4) 37
Tomioka, H. see H. Saito (4) 175
Treanor, J.J., Viral infections of the respiratory tract: prevention and treatment (4) 4

van der Hoek, Y.Y. see A.S. Bouter (4) 191
van Kessel, K.P.M. see A.S. Bouter (4) 191
Verbrugh, H.A. see W.N.M. Hustinx (4) 117
Verhoef, J., Worldwide resistance against antibiotics (4) 141
Verhoef, J. see A.S. Bouter (4) 191
Verhoef, J., The BCG controversy (4) 291

Wenisch, C. see W. Graninger (4) S29
Wéry, M., Drugs used in the treatment of sleeping sickness (human African trypanosomiasis: HAT) (4) 227
Wiese, M., B. Lindner and U. Seydel, Development of an in vitro drug screening system for *Mycobacterium leprae* based on the determination of the intrabacterial sodium to potassium ratio of individual bacterial organisms (4) 271
Wilson, A.P.R., R.N. Grüneberg and H. Neu, A critical review of the dosage of teicoplanin in Europe and the USA (4) S1
Winter, K. see A. Chibante (4) 203
Wise, R. see D. Honeybourne (4) 151

Yan, S. see D.L. Stevens (4) 297